NEW YORK (GenomeWeb News) – The Biotechnology and Biological Science Research Council said today that it has provided £10 million ($16.1 million) to launch an investment fund that will fund early-stage companies in the UK that are focused on commercializing synthetic biology technologies.

The BBSRC said the private investment company Midven will manage the fund, which will provide investments, strategic support, and help startup companies leverage private capital. Midven's Rainbow Seed Fund specializes in supporting firms that spin out from publicly-funded research programs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.